

Product datasheet for AM26232PU-N

OriGene Technologies, Inc.

9620 Medical Center Drive, Ste 200 Rockville, MD 20850, US Phone: +1-888-267-4436 https://www.origene.com techsupport@origene.com EU: info-de@origene.com CN: techsupport@origene.cn

Thrombomodulin (THBD) (EGF4 Dom.) Rat Monoclonal Antibody [Clone ID: RTM96]

Product data:

Product Type: Primary Antibodies

Clone Name: RTM96

Applications: FC, FN, WB

Recommended Dilution: Western blot: The typical starting working dilution is 1:10.

Functional assay: Inhibits the biological activity of thrombomodulin.

Flow Cytometry: The typical starting working dilution is 1:10.

Reactivity: Human

Host: Rat

Isotype: IgG2a

Clonality: Monoclonal

Immunogen: Transformant Ba/F3 cell line positive for wild-type thrombomodulin.

Specificity: Monoclonal antibody RTM96 recognizes thrombomodulin (a C-type lectin also known as

CD141), a complex molecule located on the endothelium and a key feature in the protein C

pathway. It reacts with the EGF4 domain.

Formulation: PBS

State: Purified

State: Liquid 0.2 µm filtered Ig fraction

Stabilizer: 0.1% BSA

Concentration: lot specific

Purification: Protein G Chromatography

Conjugation: Unconjugated

Storage: Store undiluted at 2-8°C.

DO NOT FREEZE!

Stability: Shelf life: one year from despatch.

Gene Name: thrombomodulin

Database Link: Entrez Gene 7056 Human

P07204





Background:

The protein C anticoagulant pathway serves as a major system for controlling coagulation and limiting inflammatory responses, and potentially decreasing endothelial cell apoptosis in response to inflammatory cytokines and ischemia. The essential components of the pathway involve thrombin, thrombomodulin, the endothelial cell protein C receptor (EPCR), protein C and protein S. Thrombomodulin binds thrombin, directly inhibiting its clotting and cell activation potential while at the same time augmenting protein C. The endothelial cell protein C receptor (EPCR) augments protein C activation by the thrombin-TM complex more than 10-fold. TM also accelerates thrombin activation of a plasma procarboxypeptidase B, named thrombin activatable fibrinolysis inhibitor or TAFI resulting in slowing clot lysis. The inhibited thrombin rapidly dissociates from thrombomodulin, regenerating the anticoagulant surface. Thrombomodulin also has direct anti-inflammatory activity, minimizing cytokine formation in the endothelium and decreasing leukocyte-endothelial cell adhesion. Thrombomodulin inhibits leukocyte binding to activated endothelium.

TM has been detected in a variety of cells and tissues in adults and during development, including astrocytes in the brain, keratinocytes, endothelial cells, mesothelial cells of the peritoneum, and circulating neutrophils, monocytes, and platelets. During fetal development, TM plays a central role in controlling the growth and survival of trophoblast cells in the placenta, a function essential for the maintenance of pregnancy.

Thrombin binding to thrombomodulin involves anion binding exosite 1 on thrombin and epidermal growth factor (EGF) domains 4 to 6 on thrombomodulin.

Synonyms:

Thrombomodulin, THRM, Fetomodulin